INTRODUCTION {#sec0005}
============

The prevailing definition of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) \[[@ref001]\] requires only one impaired neuropsychological test score, to any cognitive domain (memory, executive function, attention, language and visuospatial ability). According to this approach, impairment is typically defined by scores 1--1.5 standard deviations (SD) or more below the mean for age- and education-matched peers on culturally appropriate normative data.

However, this method has shown vulnerability to false-positive diagnostic errors \[[@ref002]\]. With this approach, Edmonds et al. \[[@ref004]\] observed a false-positive MCI diagnosis in as many as 34.2% of Alzheimer's Disease Neuroimaging Initiative (ADNI) MCI cohort, and false-negative diagnostic errors in 7.1% of ADNI's cognitively normal control group. Due to these actuarial diagnostic problems, Loewenstein et al. \[[@ref002]\], Jak et al. \[[@ref005]\], and Bondi et al. \[[@ref003]\] used an alternative classification. The Jak/Bondi criterion requires two or more tests in the same cognitive domain to be at least ≤1 SD below the demographically normative mean scores \[[@ref003]\]. Longitudinal findings show that, compared to the traditional criteria, this alternative criterion identifies more subjects that progress clinically and produces fewer subjects who return to normal neuropsychological function at follow-up \[[@ref003]\]. One explanation for the poor diagnostic accuracy of the "one reduced test" approach is that cognitively healthy individuals may acquire poor test scores by chance when several cognitive tests are administered \[[@ref006]\]. Of note, studies of patients with brain impairment of other etiology than neurodegenerative disease, do also suggest that the best balance between sensitivity and specificity is achieved with a mild cut off for impairment of 1 SD below the normative mean \[[@ref007]\].

While comprehensive neuropsychological assessment may be qualitatively better than a brief assessment with fewer tests \[[@ref003]\], a disadvantage is that comprehensive testing is time consuming, which makes it less efficient and thus less available. For efficiency, many memory clinics therefore employ brief cognitive assessments and use the prevailing definition for MCI \[[@ref001]\], despite evidence of diagnostic superiority of more comprehensive assessment with alternative impairment criteria \[[@ref002]\].

In the study of patients presenting with neurodegenerative diseases, the most meaningful outcome is a valid prediction of longitudinal cognitive change. In a cross-sectional validation study of cognitive impairment criteria, a biomarker signature considered a risk factor for development of AD can be a surrogate for this goal. The US National Institute on Aging-Alzheimer's Association (NIA-AA) suggested in 2011 a "preclinical stage of AD", defined as patients without impaired cognition on standard assessments but positive biomarker evidence for AD \[[@ref001]\]. According to this suggestion, stage 0 implies both amyloid and tau markers negative; stage 1 being lowered cerebrospinal fluid (CSF) amyloid-beta (A*β*)~42~ concentrations but negative tau markers; stage 2, lowered CSF A*β*~42~ concentrations and elevated tau concentrations; and stage 3, biomarker pattern as in stage 2 with 'subtle cognitive decline' as evidenced by reduced neuropsychological test performance. In a recent longitudinal study (*n* = 122) following memory clinic patients on average 4 years without objective cognitive impairment, we found that biomarker-based classifications according to the NIA-AA 'preclinical AD' stage 2 was the best predictor of cognitive decline, dementia, and AD dementia \[[@ref009]\]. A similar finding was reported in a five-year follow up \[[@ref010]\] where a progression rate to probable mild dementia (CDR ≥0.5) was 26% in participants classified as stage 2 at baseline, and 56% in those classified as stage 3. In a smaller 6-year longitudinal study of 81 memory clinic patients that only displayed subjective cognitive decline (SCD), findings suggested that pathological CSF A*β*~42~ (similar to stage 1), predicted conversion to dementia \[[@ref011]\]. This is in line with other studies \[[@ref012]\]. With regard to prognosis of amnestic versus non-amnestic MCI, our previous longitudinal studies revealed that MCI with memory impairment, either as a single domain deficit or in the context of a multi-domain deficit, is a stronger predictor of cognitive decline and dementia than non-amnestic MCI \[[@ref015]\].

Based on the findings described above, we chose to validate different cognitive MCI criteria against the biomarker pattern of NIA-AA stage 2 (lowered CSF A*β*~42~ concentrations and elevated CSF tau concentrations). We hypothesized that a MCI criterion, including mild amnestic deficit (Memory score 1 SD or more below normative mean), would show a stronger association with the biomarker pattern of NIA-AA stage 2, than both the conventional NIA-AA MCI criterion and an MCI criterion similar to the criterion suggested by Jak et al. and Bondi et al. \[[@ref003]\].

METHODS {#sec0010}
=======

The study was approved by the regional medical research ethics committee. All participants gave their written informed consent before taking part. All further study conduct was in line with the guidelines provided by the Helsinki declaration of 1964; revised 2013 and the Norwegian Health and Research Act.

Patients were consecutively recruited from memory clinics and neurological centers that take part in the national multicenter longitudinal collaboration Dementia Disease Initiation (DDI), aiming at detection of early biological and cognitive markers for dementia. A detailed description of inclusion ad exclusion criteria is given in Fladby et al. \[[@ref017]\]. Subjects in the present part of the study were recruited between January 2013 to November 2017. In summary, inclusion criteria were age 40--80 years, recent appearance of cognitive concerns or symptoms and a native language of Norwegian, Swedish, or Danish. Exclusion criteria were brain trauma or disorder, including clinical stroke, dementia, severe psychiatric and/or somatic disease that may account for symptoms, intellectual disability or other development disorder.

The DDI-study employ the NIA/AA \[[@ref001]\] and Jessen et al. \[[@ref018]\] criteria for stage classification, and disease diagnosis. By December 2017, CSF data as well as full data from brief cognitive screening was available for 452 patients with cognitive concerns or symptoms.

Clinical assessment {#sec0015}
-------------------

A Case Report Form (CRF) was completed for all the patients, including standardized assessments of medical history from subject and informant, physical and neurological examinations, including the Mini-Mental State Examination (MMSE) \[[@ref019]\], Geriatric Depression Scale (GDS), and brief neuropsychological screening. The brief neuropsychological assessment includes six cognitive functions. All the test scores were converted to T-scores based on available normative data.1.Delayed verbal recall (Consortium to Establish a Registry for Alzheimer's Disease (CERAD) word list) \[[@ref020]\].2.Delayed verbal recognition (CERAD word list) \[[@ref020]\].3.Visuoperceptual ability (Visual Object Space Perception (VOSP) silhouettes) \[[@ref022]\].4.Psychomotor speed (Trail Making A, TMT-A) \[[@ref023]\].5.Cognitive flexibility/divided attention (Trail Making B, TMT-B) \[[@ref023]\].6.Phonetic word fluency (Controlled Oral Word Association Test, COWAT) \[[@ref024]\].

We tested the three following neuropsychological algorithms against the NIA-AA stage 2:(1)A stringent version of the NIA-AA MCI criterion \[[@ref001]\], as employed in the DDI study: at least one test score in any cognitive domain similar to or below T-score 35.(2)A criterion similar to the suggestion of Jak et al. \[[@ref005]\] and Bondi et al. \[[@ref003]\]: at least two test scores in any cognitive domain below T-score 40.(3)Amnestic MCI: at least one test score below T-score 40, including at least one memory test.

Additionally, these algorithms were tested independently against the criteria for abnormal A*β*~42~, total tau (T-tau), and phosphorylated tau (P-tau) \[[@ref025]\].

Biomarkers {#sec0020}
----------

CSF samples were obtained by lumbar puncture using a standardized protocol. Lumbar puncture was performed before noon, and CSF was collected in polypropylene tubes (Thermo Nunc) and centrifuged within 4 h at 2000 *g* for 10 min at room temperature. The supernatant was transferred to new tubes and frozen at --80°C prior to analysis. All CSF samples were analyzed at the Department of Interdisciplinary Laboratory Medicine and Medical Biochemistry at Akershus University Hospital, and samples from other sites were frozen before sending to this laboratory. We analyzed CSF concentrations of T-tau, P-tau~181~, and A*β*~42~ by using ELISA (Innotest *β*-Amyloid (1--42), Innotest h-Tau Ag and Innotest Phospho-Tau (181P), Fujirebio, Ghent Belgium. The following cut-off values for CSF T-tau and P-tau abnormality were applied according to the laboratory recommendations (modified from Sjögren et al. 2001) \[[@ref025]\]; t-tau \>300 pg/ml for age \<50 years, \>450 pg/ml for age 50--69 years, and \>500 pg/ml for age ≥70 years and p-tau ≥80 pg/ml. An optimal cut-off at CSF A*β*~1 - 42~ \<708 for amyloid plaque pathology was determined following DDI PET \[^18^F\]-Flutemetamol uptake studies \[[@ref026]\]. NIA-AA stage 2 classification have both pathological A*β*~42~ and T-tau, showing evidence of amyloidosis and neurodegeneration.

Statistics {#sec0025}
----------

Descriptive statistics of the demographic, clinical, behavioral, and cognitive characteristics of the patient population was analyzed. Group comparisons were tested using Pearson's Chi-square for categorical variables and independent samples *t*-tests for continuous variables. Odds ratios for occurrence of NIA-AA stage 2, based on the three neuropsychological algorithms specified in the introduction as well as age and years of education was estimated with logistic regression analysis. Univariate analyses were first performed for variables reported in [Table 3](#jad-67-jad180964-t003){ref-type="table"}, and significant factors were included in the multivariate analysis. Results of the multivariate analysis are presented with odds ratios (OR) with 95% confidence intervals (CI) and *p*-values. All tests were performed at a 5% significance level. Similar analyses were performed with the employed criteria for abnormal A*β*~42~, T-tau, and P-tau as dependent variables. The Statistical Package for Social Sciences (SPSS) version 25 was used.

RESULTS {#sec0030}
=======

Demographic, clinical, and cognitive scores for the patient population are provided in [Table 1](#jad-67-jad180964-t001){ref-type="table"}. [Table 2](#jad-67-jad180964-t002){ref-type="table"} shows scores for patients fulfilling the biomarker pattern of NIA-AA stage 2 criterion (*n* = 53) or not (*n* = 398). The two groups are significantly different on most of the variables, but similar with regard to gender, years of education as well as on three of the six neuropsychological tests (COWAT, TMT-A, and VOSP silhouettes).

###### 

Demographic, clinical, and cognitive scores for the patient population

  Variables                                    All patients (*n* = 452)
  ------------------------------------------ ----------------------------
  Mean age (range) (SD)                          63.2 (40--84) (9.3)
  Female (%)                                             49.3
  Education, y (range) (SD)                       13.7 (7--22) (3.3)
  MMSE (range) (SD)                              28.5 (20--30) (1.8)
  A*β*~42~, ng/l (range) (SD)                 955.28 (300--1880) (291.0)
  T-tau, ng/l (range) (SD)                    376.71 (75--1370) (226.8)
  P-tau, ng/l (range) (SD)                      59.66 (16--185) (28.1)
  CERAD, recall, T-score (range) (SD)            46.8 (14--69) (14.4)
  CERAD, recognition, T-score (range) (SD)     46.7 (10.0--57.6) (14.7)
  COWAT, T-score (range) (SD)                    48.4 (24--77) (9.9)
  TMT-A, T-score (range) (SD)                    45.2 (12--74) (10.5)
  TMT-B, T-score (range) (SD)                    46.1 (9--76) (11.3)
  VOSP silhouettes, T-score (range) (SD)         48.5 (15--70) (11.2)

###### 

Demographic, clinical, and cognitive scores for patients fulfilling NIA-AA stage 2 criterion or not

  Variables                                   Fulfilling NIA-AA stage 2 (*n* = 53)   Not fulfilling NIA-AA stage 2 (*n* = 398)    *p*
  ------------------------------------------ -------------------------------------- ------------------------------------------- -------
  Mean age (range) (SD)                               67.8 (50--81) (7.8)                       62.6 (40--84) (9.3)              0.001
  Male/female (n)                                           197/200                                    31/22                     0.45
  Education, y (range) (SD)                            13.9(7--20) (3.4)                        13.7 (7--22) (3.3)               0.78
  MMSE (range) (SD)                                    26.9(21--30) (2.3)                       28.7 (20--30) (1.6)              0.001
  A*β*~42~, ng/l (range) (SD)                        557.3(300--700) (95.1)                 1008.3 (300--1880) (266.1)           0.001
  T-tau, ng/l (range) (SD)                          783.0(443--1370) (237.4)                 322.6 (75--1170) (160.4)            0.001
  P-tau, ng/l (range) (SD)                           108.1(63--185) (31.4)                     53.2 (16--185) (20.4)             0.001
  CERAD, recall, T-score (range) (SD)                 34.5 (14--69) (15.2)                     48.5 (14--69) (13.5)              0.001
  CERAD, recognition, T-score (range) (SD)           26.5 (10.0--58) (17.6)                    48.3 (10-- 58) (13.6)             0.001
  COWAT, T-score (range) (SD)                         49.0 (26--69) (9.5)                      48.3 (24--77) (10.0)              0.62
  TMT-A, T-score (range) (SD)                         43.6 (12--66) (10.4)                     45.4 (14--74) (10.5)              0.24
  TMT-B, T-score (range) (SD)                         41.7 (9--70) (14.4)                      46.6 (11--76) (10.8)              0.02
  VOSP silhouettes, T-score (range) (SD)              46.2 (22--70) (11.0)                      48.8(15--70) (11.3)              0.12

###### 

Univariate and multivariate regression analysis \[dependent variable: NIA-AA stage 2 = lowered cerebrospinal fluid (CSF) A*β*~42~ concentrations, and neurodegeneration (elevated CSF tau concentrations)\]

  Variable                                                                    Univariate Analysis OR (95% CI)    *p*    Multivariate Analysis OR (95% CI)    *p*
  -------------------------------------------------------------------------- --------------------------------- ------- ----------------------------------- -------
  One test or more \<T = 40, including at least one memory test                       5.7 (3.1--10.6)           0.001            4.4 (1.9--10.4)            0.001
  Age at inclusion                                                                    1.1 (1.0--1.1)            0.001            1.1 (1.0--1.1)             0.007
  Two or more tests \<T = 40 in any cognitive domain                                  3.9 (2.1--7.0)            0.001            2.2 (0.9--5.5)             0.093
  One test or more \<T = 35 in any cognitive domain (NIA-AA MCI criterion)            2.9 (1.6--5.4)            0.001            0.5 (0.2--1.5)             0.243
  Years of education                                                                  1.0 (0.9--1.1)            0.77                                       

Univariate logistic regression analysis showed significant associations with the dependent variable (NIA-AA stage 2) for amnestic MCI (*n* = 144) (OR = 5.7, CI 3.1-10.6, *p* = 0.001), age at inclusion (OR = 1.1, CI 1.0-1.1, *p* = 0.001), for the MCI condition requiring two or more tests below T = 40 in any cognitive domain (*n* = 152) (OR = 3.9, CI 2.1-7.0, *p* = 0.001) and for the condition requiring one test or more similar to or below T = 35 in any cognitive domain (NIA-AA MCI criterion) (*n* = 204) (OR = 2.9, CI 1.6-5.4, *p* = 0.001) ([Table 3](#jad-67-jad180964-t003){ref-type="table"}). Only the amnestic variant of MCI (OR = 4.4, CI 1.9-10.4, *p* = 0.001) and age at inclusion (OR = 1.1, CI 1.0-1.1, *p* = 0.007) remained significant in the multivariate analysis. Similar results were revealed both in univariate and in multivariate analysis with abnormal levels of T-tau, P-tau, and A*β*~42~ as dependent variables. In multivariate analysis the association was significant for all the variables with the amnestic variant of MCI, T-tau (OR = 3.1, CI 1.7-5.9, *p* = 0.001), P-tau (OR = 2.1, CI 1.1-4.1, *p* = 0.023), and A*β*~42~ (OR = 2.2, CI 1.2-4.0, *p* = 0.01). Similar findings were evident for age at inclusion, T-tau (OR = 1.0, CI 1.0-1.1, *p* = 0.014), P-tau (OR = 1.1, CI 1.0-1.1, *p* = 0.001) as well as A*β*~42~ (OR = 1.1, CI 1.0-1.1, *p* = 0.001). Additionally, abnormal level of A*β*~42~ was in multivariate analysis significantly associated with the MCI condition requiring two or more tests below T = 40 in any cognitive domain (OR = 2.3, CI 1.2-4.4, *p* = 0.017).

DISCUSSION {#sec0035}
==========

The main finding of this study is that amnestic MCI, including at least one memory test below T-score 40, outperformed both the conventional NIA-AA MCI criterion and the MCI condition similar to the criterion suggested by Bondi et al. and Edmonds et al. \[[@ref003]\]. Amnestic MCI was the only MCI criterion that was significantly associated with the biomarker pattern of NIA-AA stage 2 in multivariate regression analysis. While the odds ratio for occurrence of NIA-AA stage 2 was high (OR: 4.4) for patients classified according to amnestic MCI, it was associated with a low probability of NIA-AA stage 2 (OR: 0.5) for patients classified according to the conventional NIA-AA MCI criterion. Age at inclusion was also slightly associated (OR: 1.1) with the biomarker pattern of NIA-AA stage 2.

Similar results were also evident when the same independent variables (age, years of education and abnormal levels of CSF T-tau, P-tau, and A*β*~42~) were tested independently in multivariate analysis against the employed MCI criteria. Of particular interest is that the conventional MCI criterion was not associated with any of the independent variables in the multivariate analysis.

The NIA-AA stage 2 has been found to increase the risk of subsequent cognitive decline in patients with no or only subjective cognitive decline at baseline \[[@ref009]\]. The rather mild amnestic impairment criterion used in this study showed a stronger association with the biomarker-pattern characteristic of this stage, than the most commonly used NIA-AA MCI criterion \[[@ref001]\] and a variant of the Jak/Bondi criterion \[[@ref005]\]. This suggests that the amnestic MCI criterion as applied here is precise and possibly predictive of later cognitive decline in cases where a brief neuropsychological protocol is available. The association of the amnestic MCI criterion with lowered CSF A*β*~42~ concentrations and elevated CSF tau concentrations (as in NIA-AA stage 2), suggests that those who display mild memory impairment are most likely to also display hallmark AD biomarker pathology, according to the NIA-AA suggestion from 2011. However, it is necessary to bear in mind that the amyloid cascade hypothesis, implying lowered CSF A*β*~42~ concentrations as the initial sequence of events in AD, recently has been challenged. Studies have found low correlations between AD biomarkers across disease stages \[[@ref027]\], a considerable proportion of subjects with MCI develop AD in the absence of pathological amyloid \[[@ref010]\], and many elderly have lower CSF A*β* levels but normal cognitive function \[[@ref029]\]. A recent Swedish study found that 46% of cognitively well-functioning 70-year-olds had at least one pathological AD biomarker \[[@ref030]\]. While associations between MCI classifications and biomarkers are informative, the true test and validation of MCI criteria requires longitudinal follow up. With slightly different test batteries, our previous longitudinal studies showed that MCI with memory impairment, either as a single domain deficit or in the context of a multi-domain deficit, is a stronger predictor of subsequent cognitive decline and dementia than non-amnestic MCI \[[@ref015]\]. This indicates that the present findings may have some interest beyond the association with pathological CSF biomarkers at baseline. In a two-year follow up study, Hessen et al. \[[@ref015]\] found that 29% percent of patients with pure amnestic MCI and 59% percent of patients with amnestic, multi domain MCI converted to dementia as opposed to only 10% of patients with non-amnestic MCI. In the present study, both the NIA-AA MCI criterion \[[@ref001]\] and a variant of the criterion suggested by Jak et al. and Bondi et al. \[[@ref003]\] do not require memory problems and thus, may contain many subjects with possibly more benign non-amnestic MCI.

The relatively poor association, in a multivariate context, between the condition similar to the criterion suggested by Jak et al. and Bondi et al. \[[@ref003]\] (in this study, at least two tests in any cognitive domain below T-score 40) and the biomarker pattern of NIA-AA stage 2, may be explained by the different preconditions in this study and the original works by Jak et al. \[[@ref005]\] and Bondi et al. \[[@ref003]\]. They employed somewhat more comprehensive neuropsychological assessment than the brief assessment in this work. Furthermore, their seemingly lenient MCI criterion (only 1 SD below expected mean) is possibly not so lenient, as this criterion differ from other criteria with the requirement of 2 mildly impaired neuropsychological tests scores (--1 SD) in the same cognitive domain. Based on this they achieved a robust MCI score with a higher percentage of stable MCI subjects (i.e., did not revert back to normal test scores at follow up) and a higher percentage of subjects that converted to dementia at follow-up, than patients classified according to more typical MCI criteria \[[@ref001]\]. This kind of criterion has also shown distinct cortical atrophy characteristics, not captured by the traditional criteria \[[@ref031]\].

Previous reports seem to suggest that a comprehensive neuropsychological assessment is superior to brief cognitive assessments. However, this is not universally supported. One study found that single neuropsychological tests can be superior to biomarkers as predictors of cognitive decline, in particular tests of learning and memory \[[@ref032]\]. Another study that explored the best combination of multiple AD biomarkers and neuropsychological tests in predicting subsequent decline, found that CSF t-tau/amyloid and MRI biomarkers, together with the combination of only two neuropsychological tests of memory and executive function were the best predictors \[[@ref033]\]. Among several single-predictor models (biomarkers and neuropsychological test scores), both entorhinal cortex volume and TMT-B had similar predictive utility as multimarker predictors at determining those that would deteriorate clinically over 3 years \[[@ref033]\]. Similar utility of neuropsychological testing as compared with neurobiological metrics have been reported in several other studies \[[@ref034]\]. Taken together, these findings suggests that the prediction of subsequent decline in the context of MCI do not necessarily require a comprehensive neuropsychological evaluation, supporting further exploration of the utility of brief assessments in this endeavor.

The present study has some limitations. Our motivation for utilizing NIA-AA 'preclinical AD' stage 2 \[[@ref001]\] is that this biological profile was the best predictor of cognitive decline, dementia, and AD dementia in our 4--6 year follow up of SCD patients \[[@ref009]\]. NIA-AA recently published an updated research framework based on a biological definition of AD to replace the guidelines from 2011 \[[@ref037]\]. Imaging and/or biofluid biomarkers for A*β* deposition (A), neurofibrillary pathology (T), and neurodegeneration (N) are categorized as separate biomarker signatures \[AT (N)\], the first two (A,T) as AD-specific whereas the third (N) signifies neurodegeneration that also may be seen in other diseases. Thus, a possible problem with the NIA-AA 'preclinical AD' stage 2 is the inclusion of markers both specific for AD (lowered CSF A*β*~42~ and elevated CSF P-tau) as well markers that also is associated with other etiologies than AD (elevated CSF T-tau) \[[@ref037]\]. As the novel research framework allows for better differentiation between AD specific markers and markers associated with suspected non-Alzheimer pathologic change, this framework has a probable advantage over the older classification, and should be validated against cognitive signatures and criteria for cognitive impairment, and tested in future longitudinal studies of persons at risk for cognitive decline and dementia. Another limitation of the study is the cross-sectional design that precludes interpretation of how cognitive functioning develops during the course of the disorder.

In conclusion, we found that amnestic MCI based on brief neuropsychological testing and a MCI criterion customized to this test battery is significantly associated with CSF biomarkers for cognitive decline. In contrast, when we used the prevailing NIA-AA MCI criterion, non-significant associations were found. However, since the prevalence of pathological biomarkers for cognitive decline and AD is very common, the clinical significance of the present findings depends on longitudinal validation.
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